Radiation Oncology Simultaneous Integrated Boost of Biopsy Proven, Mri Defined Dominant Intra-prostatic Lesions to 95 Gray with Imrt: Early Results of a Phase I Nci Study

Background: To assess the feasibility and early toxicity of selective, IMRT-based dose escalation (simultaneous integrated boost) to biopsy proven dominant intra-prostatic lesions visible on MRI.

[1]  Sheng Xu,et al.  Fusion of real-time transrectal ultrasound with pre-acquired MRI for multi-modality prostate imaging , 2007, SPIE Medical Imaging.

[2]  Christopher Bobonich.  (G.R.F.) Ferrari City and Soul in Plato's Republic. Pp. 130. Chicago and London: The University of Chicago Press, 2005. Paper, £12, US$17. ISBN: 978-0-226-24437-2. , 2007, The Classical Review.

[3]  Heinz-Peter Schlemmer,et al.  MRI-guided biopsy of the prostate increases diagnostic performance in men with elevated or increasing PSA levels after previous negative TRUS biopsies. , 2006, European urology.

[4]  Tom W J Scheenen,et al.  IMRT boost dose planning on dominant intraprostatic lesions: gold marker-based three-dimensional fusion of CT with dynamic contrast-enhanced and 1H-spectroscopic MRI. , 2006, International journal of radiation oncology, biology, physics.

[5]  Joos V Lebesque,et al.  Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  H. Huizenga,et al.  Systematic review of the effect of radiation dose on tumor control and morbidity in the treatment of prostate cancer by 3D-CRT. , 2006, International journal of radiation oncology, biology, physics.

[7]  P. Koper,et al.  Localized volume effects for late rectal and anal toxicity after radiotherapy for prostate cancer. , 2005, International journal of radiation oncology, biology, physics.

[8]  Daniel W. Miller,et al.  Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. , 2005, JAMA.

[9]  P. Koper,et al.  Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy. , 2005, International journal of radiation oncology, biology, physics.

[10]  R. Eeles,et al.  Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects , 2005, British Journal of Cancer.

[11]  Gabor Fichtinger,et al.  Design of a novel MRI compatible manipulator for image guided prostate interventions , 2005, IEEE Transactions on Biomedical Engineering.

[12]  J. Pouliot,et al.  Inverse planning for HDR prostate brachytherapy used to boost dominant intraprostatic lesions defined by magnetic resonance spectroscopy imaging. , 2004, International journal of radiation oncology, biology, physics.

[13]  A. Hanlon,et al.  Radiation therapy dose escalation for prostate cancer: a rationale for IMRT , 2003, World Journal of Urology.

[14]  George Starkschall,et al.  Prostate cancer radiation dose response: results of the M.D. Anderson phase III randomized trial , 2003 .

[15]  George Starkschall,et al.  Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. , 2002, International journal of radiation oncology, biology, physics.

[16]  Cedric Yu,et al.  Magnetic resonance spectroscopic imaging-guided brachytherapy for localized prostate cancer. , 2001, International journal of radiation oncology, biology, physics.

[17]  B Pickett,et al.  Forward or inversely planned segmental multileaf collimator IMRT and sequential tomotherapy to treat multiple dominant intraprostatic lesions of prostate cancer to 90 Gy. , 2001, International journal of radiation oncology, biology, physics.

[18]  H M Sandler,et al.  Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. , 2000, Urology.

[19]  L Verhey,et al.  Static field intensity modulation to treat a dominant intra-prostatic lesion to 90 Gy compared to seven field 3-dimensional radiotherapy. , 1999, International journal of radiation oncology, biology, physics.

[20]  A. Jemal,et al.  Cancer Statistics, 2007 , 2007, CA: a cancer journal for clinicians.

[21]  C. N. Coleman,et al.  Transrectal prostate biopsy and fiducial marker placement in a standard 1.5T magnetic resonance imaging scanner. , 2006, The Journal of urology.

[22]  Butler Wm,et al.  Wei JT, Dunn RL, Litwin MS, Sandler HM, Sanda MG. Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology 2000;56:899-905. , 2006 .